1. Home
  2. EYPT vs CFFN Comparison

EYPT vs CFFN Comparison

Compare EYPT & CFFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYPT
  • CFFN
  • Stock Information
  • Founded
  • EYPT 1987
  • CFFN 1893
  • Country
  • EYPT United States
  • CFFN United States
  • Employees
  • EYPT N/A
  • CFFN N/A
  • Industry
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • CFFN Savings Institutions
  • Sector
  • EYPT Industrials
  • CFFN Finance
  • Exchange
  • EYPT Nasdaq
  • CFFN Nasdaq
  • Market Cap
  • EYPT 741.0M
  • CFFN 813.3M
  • IPO Year
  • EYPT 2005
  • CFFN 1999
  • Fundamental
  • Price
  • EYPT $11.09
  • CFFN $6.09
  • Analyst Decision
  • EYPT Strong Buy
  • CFFN Hold
  • Analyst Count
  • EYPT 7
  • CFFN 1
  • Target Price
  • EYPT $24.29
  • CFFN $6.50
  • AVG Volume (30 Days)
  • EYPT 643.4K
  • CFFN 721.9K
  • Earning Date
  • EYPT 08-06-2025
  • CFFN 07-23-2025
  • Dividend Yield
  • EYPT N/A
  • CFFN 5.58%
  • EPS Growth
  • EYPT N/A
  • CFFN N/A
  • EPS
  • EYPT N/A
  • CFFN 0.47
  • Revenue
  • EYPT $51,898,000.00
  • CFFN $192,483,000.00
  • Revenue This Year
  • EYPT N/A
  • CFFN $10.56
  • Revenue Next Year
  • EYPT N/A
  • CFFN $11.73
  • P/E Ratio
  • EYPT N/A
  • CFFN $12.95
  • Revenue Growth
  • EYPT 2.99
  • CFFN N/A
  • 52 Week Low
  • EYPT $3.91
  • CFFN $4.90
  • 52 Week High
  • EYPT $13.99
  • CFFN $7.20
  • Technical
  • Relative Strength Index (RSI)
  • EYPT 61.85
  • CFFN 52.98
  • Support Level
  • EYPT $10.22
  • CFFN $6.07
  • Resistance Level
  • EYPT $11.28
  • CFFN $6.18
  • Average True Range (ATR)
  • EYPT 0.71
  • CFFN 0.12
  • MACD
  • EYPT 0.04
  • CFFN 0.02
  • Stochastic Oscillator
  • EYPT 89.89
  • CFFN 64.41

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About CFFN Capitol Federal Financial Inc.

Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank, Capitol Federal Savings Bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It primarily serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.

Share on Social Networks: